Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
Histopathology · 2024-09 · 85 (3) · 371-382
DOI: 10.1111/his.15213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 06.06.2024. Verfasst von Natthawadee Laokulrath und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2)‐enriched breast cancer benefits significantly from anti‐HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti‐HER2 regimens. Recently, the emerging eligibility of patients with HER2‐low breast cancers for a novel HER2‐targeted antibody–drug conjugate (T‐DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0–1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore.
- Department of Anatomical Pathology, Singapore General Hospital, Singapore.
- Department of Pathology, Sengkang General Hospital, Singapore.
- Division of Anatomical Pathology, Changi General Hospital, Singapore.
- Duke-NUS Medical School, Singapore.
ORCID-Profile: Jabed Iqbal, Benjamin Yongcheng Tan, Emad Rakha, Puay Hoon Tan
Zitieren
APA
Laokulrath, N., Gudi, M., Salahuddin, S. A., Chong, A. P. Y., Ding, C., Iqbal, J., Leow, W. Q., Tan, B. Y., Tse, G., Rakha, E., & Tan, P. H. (2024). Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges. Histopathology, 85(3), 371-382. https://doi.org/10.1111/his.15213
Vancouver
Laokulrath N, Gudi M, Salahuddin SA, Chong APY, Ding C, Iqbal J, et al. Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges. Histopathology. 2024;85(3):371-382. doi:10.1111/his.15213
BibTeX
@article{Laokulrath2024,
author = {Laokulrath, Natthawadee and Gudi, Mihir and Salahuddin, Syed Ahmed and Chong, Angela Phek Yoon and Ding, Cristine and Iqbal, Jabed and Leow, Wei Qiang and Tan, Benjamin Yongcheng and Tse, Gary and Rakha, Emad and Tan, Puay Hoon},
title = {Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges},
journal = {Histopathology},
year = {2024},
volume = {85},
number = {3},
pages = {371--382},
doi = {10.1111/his.15213}
}
EUVIMED